QPEX BIOPHARMA is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings.
Location: Canada
Employees: 11-50
Total raised: $53M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Adams Stre... | adamsstree... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.12.2019 | - | $20M | - |
| 22.10.2018 | Series A | $33M | New Enterp... |
Mentions in press and media 9
| Date | Title | Description |
| 16.12.2019 | Qpex Biopharma Gets $20M From BARDA | San Diego-based biopharmaceuticals developer Qpex Biopharma |
| 17.07.2019 | FDA approves new triple-drug antibiotic from Merck | Bacteria that cause the cUTIs and are treatable with Recarbrio include Gram-negative organisms like Enterobacter cloacea, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa. Susceptible bacteria that ca... |
| 22.10.2018 | Qpex Biopharma Closes $33M in Series A Financing | Qpex Biopharma, a San Diego, CA-based infectious disease company, raised $33m Series A financing. The round was led by New Enterprise Associates with participation from Adams Street Partners, LYZZ Capital, Hatteras Venture Partners and Stan... |
| 22.10.2018 | Qpex Biopharma Announces $33M Series A | SAN DIEGO, CA, Qpex Biopharma today announced the closing of a $33 million Series A financing and launch of the infectious disease company. >> Click here for more funding data on Qpex Biopharma >> To export Qpex Biopharma fu... |
| 22.10.2018 | New Enterprise Associates Leads $33M Series A for Qpex Biopharma | Qpex Biopharma today announced the closing of a $33 million Series A financing and launch of the infectious disease company. Qpex is focused on developing new antibiotics to combat the growing threat of global antimicrobial resistance. Upon... |
| 22.10.2018 | The Medicines Co. spin-out Qpex launches with $33M in VC funding for antibiotics development | Other venture capital firms participating in the financing include Adams Street Partners, LYZZ Capital, Hatteras Venture Partners and Stanford University Draper Fund, along with additional funding by the Department of Health and Human Servi... |
| 22.10.2018 | Qpex Biopharma Finds $33M For Antibiotics Development | San Diego-based Qpex Biopharma announced this morning that it has raised $33M in a Series A funding round, to launch its efforts to battle drug-resistant infections. According to Qpex, the funding was led by New Enterprise Associates, and a... |
| - | The Medicines Co. spin-out Qpex launches with $33M in VC funding for antibiotics development | A venture capital firm that was an early investor in companies like Tesaro and CRISPR therapeutics is among the leaders in a new spin-out from The Medicines Co. San Diego-based Qpex Biopharma announced its launch Monday with a $33 million S... |
| - | FDA approves new triple-drug antibiotic from Merck | The Food and Drug Administration has approved a new antibiotic drug for patients with certain infections who have run out of options. Kenilworth, New Jersey-based Merck & Co. said Wednesday that the FDA had approved Recarbrio (imipenem,... |